All News

The system will be part of a NPH study.

The drug now has a new approved dosing schedule.

The agency granted the treatment with 510(k) clearance.

ResVita will use the money to develop a treatment for severe atopic dermatitis.

Move comes amid company’s shift to focusing on healthcare innovation exclusively.

Submission to focus on maintenance therapy in adults with moderately to severely active Crohn’s disease.

Appointment comes amid resignation of Marie-France Tschudin from company executive committee.

Embrace the tools that solve real problems and make life easier.

After concerns raised by multiple supply chain participants over readiness, the agency steps back.

Results based on a 2022 global PatientView survey.

In this Q&A, Matt Smith, vice president of research site development, Slope, discusses the competition pharma companies and trial sponsors face when trying to become a sponsor of choice and build trust with sites and patients.

New executive comes with over 15 years of experience.

Uncertainty swirls on just how effective policy competition between the EU and UK on these much-needed products will be.

Capital to be invested in company’s AI platform and discovery pipeline.

In this exclusive Q&A with Pharmaceutical Executive, Janice Chang, CEO of TransCelerate BioPharma, provides an inside look into her career journey, her work at the company, how the industry has changed in the last 10 years, as well as her thoughts on where the industry should put its efforts in clinical trials.

A look at the rise of prior authorization certified specialists (PACS)—and their value in improving patient access and outcomes.

Companies hope to accelerate fight against cancer

Strategy includes a layoff of nearly 400 employees.

The UK BioIndustry Association’s Q2 Biotech Financing Report finds improved financing, driven primarily by venture capital investment.

Deal to focus on Poseida’s commitment to cancer cell therapy.

Recent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.

Company is seeking monetary damages from the alleged violation.

Pandemic preparedness and curbing PBMs among the pending legislation that will have to wait until after summer recess.

Research concludes professional disease education leads to greater treatment adoptions.

Frederique Welgryn, global vice president for women's health, Perrigo, shares insight into the approval of Opill (norgestrel), a progestin-only contraception, in this exclusive Q&A.

Common advice for OA sufferers is joint replacement, but other options are on the horizon.

FDA stresses facility only responsible for 8% of total US hospital consumption for sterile injectable drug market, as well as the need for a reliable drug supply chain.